Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03010358
Title Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

follicular lymphoma

chronic lymphocytic leukemia/small lymphocytic lymphoma

chronic lymphocytic leukemia

prolymphocytic leukemia

hairy cell leukemia

marginal zone B-cell lymphoma

lymphoplasmacytic lymphoma

mantle cell lymphoma

Therapies

Entospletinib + Obinutuzumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
OHSU Knight Cancer Institute Portland Oregon 97239 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field